Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. [electronic resource]
Producer: 20201103Description: 2184-2197 p. digitalISSN:- 1476-5551
- Adult
- Aged
- Aged, 80 and over
- CD79 Antigens -- genetics
- Female
- High-Throughput Nucleotide Sequencing
- Humans
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Male
- Middle Aged
- Mutation
- Phosphoinositide-3 Kinase Inhibitors -- therapeutic use
- Pyrimidines -- adverse effects
- Quinazolines -- adverse effects
- Recurrence
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.